Associate Prof, Dept of HMO, @WinshipAtEmory @EmoryUniversity, Leader of Neuroendocrine Cancers Research, NET SPORE PI of GLP-1 project, Sharing own thoughts
Atlanta, GA
Joined October 2019
- Tweets2.4K
- Following792
- Followers819
- Likes7K
Po Hien Ear, PhD retweeted
“It’s been a journey” Shroff told @NBCNews. “I’ve spent my entire life trying to eradicate cancer, primarily pancreatic cancer, but also liver cancers.”
nbcnews.com/health/disease/r…
An homage to Rachna Shroff, including thoughts from her family. Please read, share & honor her memory.
Po Hien Ear, PhD retweeted
A light in our HPB oncology community is gone, much too soon
She changed what is possible for patients with cholangiocarcinoma and even saw through a Young Investigator Award in Biliary Cancers
Thinking of her family and all who loved her. RIP 🖤💐
medicine.arizona.edu/news/20…
Po Hien Ear, PhD retweeted
An unimaginable loss to our field. It is indeed so deeply inspiring that even in the face of her own sickness, she worked toward raising funds to support rare cancer research and that too for young investigators. Rest in peace 🙏🏽
Rest in peace dear Rachna. 💔 cancercenter.arizona.edu/new…
Po Hien Ear, PhD retweeted
Three days left to apply for the Nichole Borchard Foundation Research Grant. Up to $100,000 to advance high grade NEC and NET research, in honor of Nichole's life and legacy. Deadline: October 10. Apply: nanets.net/research/research…
It’s been amazing to be surrounded by these super smart people! Happy 25th Anniversary @davidasinclair lab!
Please join us for tomorrow’s seminar on GPL1 mimetic from Dr Joe Dillon (aka the awesome doctor who cloned GLP1R during his fellowship)!
Join us on Thursday 24th September for this month's NETChatter. DM for the link.
@NANETS1 @PheoPara @CureNETs @carcinoid @netcanceraware @NCFCancer @netcancerday @HealingNET1
Po Hien Ear, PhD retweeted
Kudos to @EmoryDeptofMed resident @CShi321 for leading this comprehensive review on systemic therapies in gastroenteropancreatic neuroendocrine carcinomas in the European Journal of Cancer. GEP-NEC represents an incredibly heterogeneous and challenging disease to treat. Despite years of work, platinum chemotherapy regimens remain the mainstay of treatment (indeed a suboptimal standard of care), with select patients deriving benefit from targeted therapy and immune checkpoint inhibitors. Luckily there are newer agents (especially DLL3-targeting agents), that are currently in development and appear promising. @WinshipAtEmory @OncoThor @rohit_thum @Sarbaji85064063 @ChandrikhaC @helops79 🦓💊📈
Link: ejcancer.com/article/S0959-8…
Po Hien Ear, PhD retweeted
Join us this Thursday 27th August for this month's NETChatter meeting. DM for the link.
@PheoPara @carcinoid @CarcinoidNETs @CureNETs @NANETS1 @NETawarenesss @NCFCancer @netcancerday
Thanks for the shout out @JudsonKimmel1 ! Actually, Dr Bellizzi @IHC_guy did all the hard work on the GLP1R in NEN project. I just helped to carry the study across the finish line 😊
Definitely an ongoing topic of interest among NEN pts. The @PoHienEar team article from last November was very helpful in understanding GLP expression variation among NEN types, and this article will help further in considering individual risk/reward. 👏🦓
Big thanks to @UGrewalMD & @OncoThor for leading this discussion! We still have a long way to go in terms of scientific knowledge. We are extremely grateful to have NET SPORE funding and amazing colleagues to help with this challenging project! 🙏
How does one counsel a patient with resected or still-active NET on the use of incretin mimetics such as GLP-1RA and mixed GLP1-RA/GIP1-RA (tirzepatide)?
Many such patients stand to derive substantial benefit from these drugs but there have been lingering concerns about long-term safety in terms of neuroendocrine neoplasms. While preclinical studies have shown stimulatory effect on growing NET cell lines (keep in mind, they may not accurately reflect NETs in humans), no convincing evidence from post-marketing studies has been seen.
I will freely admit that we do not have all the answers but thanks to @UGrewalMD for leading this project with @sonbol_bassam @HansHofland1 @IHC_guy @PoHienEar @CronaJoakim James Howe, Simron Singh, Jonathan Strosberg, Joseph Dillon and Jennifer Chan.
I hope you will find this useful and it will stimulate further discussion.
Disclaimer: I have no COIs regarding any of these meds.
acsjournals.onlinelibrary.wi…
Po Hien Ear, PhD retweeted
Are you a medical oncologist or an oncology fellow with interest in GI Oncology? Would you like to work at a world renowned large medical center in Minnesota? With a phenomenal multidisciplinary team...? And with lots of research opportunities...?
If so, we have an open position in GI Oncology at Mayo Clinic in Rochester.
Check it out below and apply if interested...
Also, please forward/tag anyone who may have interest.
Happy to take questions if you have any having worked here for over 15 years.
jobs.mayoclinic.org/job/roch…
Po Hien Ear, PhD retweeted
Happy to share our invited review on "Grade progression and high-grade transformation in Neuroendocrine Neoplasms" just out in @EndoCancer.
🔗 shorturl.at/UpxlF
Forever grateful to @IHC_guy for his mentorship on this and several other projects (crazy that I even know you and get to work with you). We hope that this will be a helpful guide for colleagues while dealing with this clinical challenge that I find to be incredibly hard to navigate. Thank you @NANETS1 for the nomination and co-authors @ChandrikhaC @PoHienEar @RaulSGonzalezMD @SethConcorsMD for your contribution to this work.
Po Hien Ear, PhD retweeted
Michael K. Schultz, PhD, delivered this year's O'Dorisio Memorial Lecture, honoring the enduring legacy of Tom and Sue O'Dorisio, MD. Schultz shared how their mentorship helped shape his pioneering work in neuroendocrine tumor therapy.
Read more: /
Po Hien Ear, PhD retweeted
Not long to go until this month's NETChatter. Join us at 6pm UK / 1pm EST USA. DM for the link.
Po Hien Ear, PhD retweeted
Thank you! Loved the chance to talk about taking care of patients with our @WinshipAtEmory multiD team. @UGrewalMD @PoHienEar
Po Hien Ear, PhD retweeted
Finally out!!- A critical appraisal of literature and several practical insights from surgeon extraordinaire @SethConcorsMD and team on the role of primary tumor resection for patients with small bowel neuroendocrine tumors in the setting of metastatic disease @EndoCancer. @WinshipAtEmory @TheGutOncLab
erc.bioscientifica.com/view/…
On a personal note- I do think there is a role for PTR among patients with a symptomatic primary (caveat: symptoms can be very subtle or non-specific and therefore challenging to identify). The role of PTR remains less well-defined in asymptomatic primary tumors, especially among those with relatively indolent disease.
Po Hien Ear, PhD retweeted
Big news from #ASCO2026: targeted therapies matched to tumor biology show promise in pancreatic cancer. Winship's Kevin Kalinsky, MD, MS, FASCO, explains why this is a major advance for precision medicine and patients.
We’re excited to recruit a Research Scientist to join our NET Team.
@WinshipAtEmory @NANETS1 @CureNETs
Please help share:
lnkd.in/dMDDD3pz
Po Hien Ear, PhD retweeted
Thank you for highlighting @WinshipAtEmory
Excited to continue working in this direction and hopefully ensure wider access to germline testing for patients with neuroendocrine neoplasms.
At #ASCO2026, Winship GI medical oncologist @UGrewalMD shared promising research highlighting the potential value of universal germline genetic testing for patients with neuroendrocrine neoplasms, findings that could help inform future treatment guidelines and care.
Po Hien Ear, PhD retweeted
Researchers: join us Nov. 16–18 in Boston for the 2026 NETRF Neuroendocrine Cancer Research Symposium, THE place for basic & translational NEC/NET science.
Free registration. Abstracts due June 10.
Details: netrf.org/for-researchers/20…
